150,000 Shares in Aspen Aerogels, Inc. $ASPN Purchased by Hartree Partners LP

Key Points

• Hartree Partners LP has acquired a new stake in Aspen Aerogels, purchasing 150,000 shares valued at approximately $958,000.
• Aspen Aerogels reported a negative EPS of ($0.04) for the last quarter, exceeding analysts' expectations, but a revenue drop of 33.8% compared to the previous year.
• Institutional investors now hold 97.64% of Aspen Aerogels, with multiple hedge funds significantly increasing their positions in the company during the 1st quarter.

Hartree Partners LP bought a new position in shares of Aspen Aerogels, Inc. (NYSE:ASPN - Free Report) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 150,000 shares of the construction company's stock, valued at approximately $958,000. Hartree Partners LP owned approximately 0.18% of Aspen Aerogels at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Aspen Aerogels by 311.0% in the 4th quarter. JPMorgan Chase & Co. now owns 105,591 shares of the construction company's stock valued at $1,254,000 after purchasing an additional 79,901 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of Aspen Aerogels by 158.6% in the fourth quarter. Wells Fargo & Company MN now owns 216,049 shares of the construction company's stock worth $2,567,000 after buying an additional 132,489 shares during the last quarter. Envestnet Asset Management Inc. raised its holdings in Aspen Aerogels by 118.4% in the fourth quarter. Envestnet Asset Management Inc. now owns 47,262 shares of the construction company's stock valued at $561,000 after acquiring an additional 25,620 shares in the last quarter. Russell Investments Group Ltd. raised its holdings in Aspen Aerogels by 654.9% in the fourth quarter. Russell Investments Group Ltd. now owns 25,237 shares of the construction company's stock valued at $300,000 after acquiring an additional 21,894 shares in the last quarter. Finally, Invesco Ltd. raised its holdings in Aspen Aerogels by 3.5% in the fourth quarter. Invesco Ltd. now owns 50,871 shares of the construction company's stock valued at $604,000 after acquiring an additional 1,724 shares in the last quarter. 97.64% of the stock is currently owned by hedge funds and other institutional investors.

Aspen Aerogels Stock Performance

Shares of Aspen Aerogels stock traded up $0.20 on Tuesday, reaching $7.13. 1,275,481 shares of the company were exchanged, compared to its average volume of 2,772,213. The company has a debt-to-equity ratio of 0.34, a quick ratio of 3.31 and a current ratio of 3.98. The company's 50-day moving average is $6.95 and its two-hundred day moving average is $6.69. The firm has a market cap of $586.90 million, a price-to-earnings ratio of 43.31 and a beta of 2.73. Aspen Aerogels, Inc. has a 1-year low of $4.16 and a 1-year high of $32.31.

Aspen Aerogels (NYSE:ASPN - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The construction company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.12) by $0.08. The business had revenue of $78.02 million during the quarter, compared to analyst estimates of $72.53 million. Aspen Aerogels had a negative net margin of 78.53% and a positive return on equity of 2.92%. The company's quarterly revenue was down 33.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.21 earnings per share. Aspen Aerogels has set its FY 2025 guidance at -3.860--3.730 EPS. As a group, research analysts expect that Aspen Aerogels, Inc. will post 0.17 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently issued reports on ASPN. Canaccord Genuity Group cut their price target on shares of Aspen Aerogels from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Friday, August 8th. Barclays lowered Aspen Aerogels from an "equal weight" rating to an "underweight" rating and boosted their price objective for the company from $7.00 to $16.00 in a report on Monday, August 11th. Finally, Oppenheimer downgraded Aspen Aerogels from an "outperform" rating to a "market perform" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have given a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat.com, Aspen Aerogels presently has a consensus rating of "Moderate Buy" and an average price target of $19.50.

Insider Buying and Selling at Aspen Aerogels

In other news, CAO Santhosh P. Daniel sold 4,410 shares of Aspen Aerogels stock in a transaction that occurred on Tuesday, August 12th. The stock was sold at an average price of $7.31, for a total transaction of $32,237.10. Following the sale, the chief accounting officer owned 19,879 shares of the company's stock, valued at approximately $145,315.49. The trade was a 18.16% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 3.40% of the company's stock.

Aspen Aerogels Profile

Aspen Aerogels, Inc designs, develops, manufactures, and sells aerogel insulation products primarily for use in the energy infrastructure and sustainable insulation materials markets in the United States, Asia, Canada, Europe, and Latin America. It operates in two segments, Energy Industrial and Thermal Barrier.